Atara Biotherapeutics' SEC filings document the company's allogeneic EBV T-cell immunotherapy business, public common stock, and regulatory record for tabelecleucel, including 8-K disclosures tied to FDA communications, Complete Response Letter updates, and the EBVALLO Biologics License Application.
The filings also report financial results and liquidity updates, commercialization and milestone arrangements, amendments to royalty-related purchase and sale agreements, warrant issuance terms, Nasdaq continued-listing compliance notices, and proxy matters such as board elections, executive compensation, equity awards, and shareholder voting proposals.
Atara Biotherapeutics (ATRA) filed a Form 144 reporting a proposed sale of 2,048 shares of common stock on or about 08/18/2025 through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $25,169.92. The filing shows those shares were acquired on 08/15/2025 as settlement of vested restricted stock units issued under an S-8 registration plan, with payment noted as equity compensation for services rendered. The filer also reported a prior sale on 05/16/2025 of 2,218 shares for gross proceeds of $15,000.33. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information about the issuer.
Atara Biotherapeutics (ATRA) reported a pronounced change in its mid‑2025 financial position driven by transactions with Pierre Fabre and cost reductions. Total assets declined to $36.9 million at June 30, 2025 from $109.1 million at year‑end, and cash and cash equivalents were $16.9 million. Total liabilities fell to $71.9 million, and stockholders’ deficit improved to $(35.0) million.
Commercialization revenue for the six months ended June 30, 2025 was $115.7 million, reflecting recognition of deferred revenue tied to the transfer of manufacturing, inventory and related services to Pierre Fabre; deferred revenue declined from $95.1 million at year‑end to $1.6 million at June 30. Net income for the six months was $40.4 million versus a loss of $50.8 million a year earlier, producing basic earnings per share of $3.52 for the period. The company recorded restructuring charges of $11.3 million and a lease right‑of‑use impairment of $4.1 million. Management discloses substantial doubt about the company’s ability to continue as a going concern and plans to seek additional capital.
Atara Biotherapeutics reported that it announced financial results for the second quarter ended June 30, 2025 and furnished a press release as Exhibit 99.1 to its Form 8-K. The filing specifies the press release is being furnished (not "filed") and therefore is not subject to the liabilities of Sections 11 and 12(a)(2) of the Securities Act or deemed "filed" under Section 18 of the Exchange Act, and will not be incorporated by reference into other SEC filings unless expressly referenced. The Form lists the company ticker as ATRA and is signed by the Chief Accounting Officer.